Literature DB >> 25748578

Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC.

Frederick A Jakobiec1, Marcel Kool2, Anna M Stagner3, Stefan M Pfister4, Ralph C Eagle5, Alan D Proia6, Andrey Korshunov7.   

Abstract

PURPOSE: To compare immunohistochemical and genetic overlaps and differences between intraocular medulloepitheliomas and embryonal tumors with multilayered rosettes of the brain.
DESIGN: Retrospective histopathologic, immunohistochemical, and genetic analysis of 20 intraocular medulloepitheliomas.
METHODS: (1) Review of clinical data and hematoxylin-eosin-stained sections with (2) immunohistochemical staining of paraffin sections using a polyclonal antibody against the protein LIN28A, and (3) fluorescence in situ hybridization (FISH) testing for the amplification of the genetic locus 19q13.42 involving the C19MC cluster of miRNA. Ten retinoblastomas served as controls and to determine the specificity of these biomarkers for intraocular medulloepitheliomas.
RESULTS: Nineteen of the 20 intraocular medulloepitheliomas were either diffusely or focally LIN28A positive (weak, moderate, or strong). The most intense positivity correlated with aggressive behavior such as intraocular tissue invasion or extraocular extension. None of the cases studied by FISH harbored an amplicon for C19MC. The 10 retinoblastomas were LIN28A and C19MC negative.
CONCLUSION: LIN28A has a putative role in oncogenesis and is found only in embryonic cells and malignancies. Intraocular medulloepitheliomas and embryonal tumors with multilayered rosettes of the brain both display LIN28A positivity. Only the latter, however, display amplification of the 19q13.42 locus involving C19MC, implying that other causative factors are at play in intraocular medulloepitheliomas. More aggressive tumor behavior within the eye can be partially predicted by LIN28A staining intensity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25748578     DOI: 10.1016/j.ajo.2015.03.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  The Targetable Epigenetic Tumor Protein EZH2 is Enriched in Intraocular Medulloepithelioma.

Authors:  Sarah E Avedschmidt; Anna M Stagner; Ralph C Eagle; George J Harocopos; Yali Dou; Rajesh C Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-11-01       Impact factor: 4.799

Review 2.  Molecular Testing of Brain Tumor.

Authors:  Sung-Hye Park; Jaekyung Won; Seong-Ik Kim; Yujin Lee; Chul-Kee Park; Seung-Ki Kim; Seung-Hong Choi
Journal:  J Pathol Transl Med       Date:  2017-05-12

3.  High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells.

Authors:  Patrícia Benites Gonçalves da Silva; Márcia Cristina Teixeira Dos Santos; Carolina Oliveira Rodini; Carolini Kaid; Márcia Cristina Leite Pereira; Gabriela Furukawa; Daniel Sanzio Gimenes da Cruz; Mauricio Barbugiani Goldfeder; Clarissa Ribeiro Reily Rocha; Carla Rosenberg; Oswaldo Keith Okamoto
Journal:  Oncotarget       Date:  2017-03-21

4.  Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience.

Authors:  David Capper; Damian Stichel; Felix Sahm; David T W Jones; Daniel Schrimpf; Martin Sill; Simone Schmid; Volker Hovestadt; David E Reuss; Christian Koelsche; Annekathrin Reinhardt; Annika K Wefers; Kristin Huang; Philipp Sievers; Azadeh Ebrahimi; Anne Schöler; Daniel Teichmann; Arend Koch; Daniel Hänggi; Andreas Unterberg; Michael Platten; Wolfgang Wick; Olaf Witt; Till Milde; Andrey Korshunov; Stefan M Pfister; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2018-07-02       Impact factor: 17.088

5.  Early Neuroblastic and Astrocytic Differentiation Demonstrated Immunohistochemically in a Small Intraocular Medulloepithelioma.

Authors:  Frederick A Jakobiec; Fouad R Zakka; Thanos Papakostas; Shizuo Mukai
Journal:  Ocul Oncol Pathol       Date:  2017-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.